Vasgen Limited, a new speciality biotech company, has been awarded Biomedical Catalyst Feasibility funding by the Technology Strategy Board in a collaboration with Profs Bainbridge and Greenwood from the UCL Institute of Ophthalmology to conduct studies for the development of a new ocular anti-angiogenesis therapy.